APOBEC3G (A3G) is an intrinsic antiviral factor that inhibits the replication of human immunodeficiency virus (HIV) by deaminating cytidine residues to uridine. This causes guanosine-to-adenosine hypermutation in the opposite strand and results in inactivation of the virus. HIV counteracts A3G through the activity of viral infectivity factor (Vif), which promotes degradation of A3G. We report that viral protein R (Vpr), which interacts with a uracil glycosylase, also counteracted A3G by diminishing the incorporation of uridine. However, this process resulted in activation of the DNA-damage-response pathway and the expression of natural killer (NK) cell-activating ligands. Our results show that pathogen-induced deamination of cytidine and the DNA-damage response to virus-mediated repair of the incorporation of uridine enhance the recognition of HIV-infected cells by NK cells.
A r t i c l e s After exposure to human immunodeficiency virus (HIV), the acute phase of infection is characterized by high viral loads, which are counteracted by a rapid immune response 1 . The first line of defense against viral infection is the innate immune system, which uses pattern-recognition receptors to detect pathogen-associated molecular patterns. This response leads to the secretion of cytokines, which increases the expression of factors of the innate immune response, such as APOBEC3G (A3G), that limit viral replication and spread 2 .
A3G is a member of a family of cytidine deaminases known as the apolipoprotein B-editing complex (APOBEC). In addition to inhibiting HIV, members of the APOBEC3 family inhibit DNA viruses and potentially harmful retrotransposition 3 . The mechanism by which A3G inhibits HIV replication is twofold. A3G is packaged into HIV particles and deaminates cytosine residues to uracil residues in exposed stretches of viral single-stranded DNA during cDNA synthesis 4 . This editing leads to guanosine-to-adenosine hypermutation on the opposite strand, which inactivates the virus. A3G also inhibits the translocation of reverse transcriptase along template RNA, which disrupts the synthesis of cDNA 5 . The importance of A3G in disease pathogenesis resulting from infection with HIV is highlighted by the fact that genetic variation in the locus encoding A3G can be used to predict disease progression in HIV-infected people 6 .
The viral infectivity factor (Vif) of HIV type 1 (HIV-1) counteracts A3G by targeting it for proteasomal degradation, thus diminishing the amount of A3G incorporated into virus particles 7 . However, the action of Vif is not absolute, and hypermutated viral genomes have been isolated from people with full-length HIV-1 (ref. 8 ).
These sublethal mutations may influence the evolution of HIV-1 and promote the acquisition of drug resistance and evasion of the immune response 9 .
HIV-1-specific CD8 + cytotoxic T lymphocytes (CTLs) decrease viremia during the acute and chronic stages of the infection with HIV 10 but do not prevent the development of AIDS in most infected people. The HIV-1 negative factor (Nef) protein may limit the effectiveness of CTLs by downmodulating the surface expression of major histocompatibility complex (MHC) class I (refs. 11,12) . However, MHC class I inhibits the lytic activity of natural killer (NK) cells, and thus downmodulation of MHC class I by Nef may increase the susceptibility of HIV-infected cells to NK cells.
Studies of the allelic frequencies of inhibitory receptors on NK cells have provided evidence of a role for NK cells in limiting HIV infection. For example, HIV-infected people who express the NK cell inhibitory receptor KIR3DL1 and its cognate ligand HLA-Bw4 progress to AIDS at a slower rate than do those without this allelic combination 13 . This delayed progression probably results from a decrease in the activation threshold in the absence of inhibitory signals effected via HLA-Bw4, which is targeted by Nef in HIV-infected people 14 . In addition, resistance to HIV-1 among sex workers is associated with a greater incidence of genes encoding such inhibitory receptors that lack their cognate inhibitory HLA ligand, which could lower the threshold for NK cell activation 15 .
NK cell-activating signals also influence the progression of HIV disease. Infected people who express KIR3DS1 and HLA-Bw4-80Ile progress more slowly to AIDS 16 because of higher KIR3DS1 expression by HLA-Bw4 + people 17 . Ligands detected by the NK cell-activating A r t i c l e s receptor NKG2D also stimulate recognition by NK cells. These ligands represent a diverse family of proteins commonly upregulated in viral infection 18 and can affect recognition by NK cells in HIV-infected people 19 . In sum, these studies have provided evidence that NK cells influence the progression of disease after infection with HIV and that strategies aimed at enhancing NK cell activity may benefit HIVinfected people.
Published reports have linked the expression of NKG2D-activating ligands to viral protein R (Vpr) 20 . Known cellular targets bound by Vpr are DNA-repair proteins, including the uracil DNA glycosylases UNG2 and SMUG1 (refs. 21,22) . However, the role of these DNA-repair proteins in the normal functioning of Vpr and their potential role in the pathogenesis of disease after infection with HIV is unknown.
Here we examined the effect of A3G, Vif and Vpr on the recognition of HIV-infected cells by NK cells. Our studies identified a role for A3G in alerting NK cells to the presence of viral pathogens and showed how HIV evades this response. Specifically, we provide evidence that pathogen-induced cytidine deamination and the DNA-damage-response to virus-mediated repair of uridine incorporation acted as intrinsic antiviral responses by upregulating the expression of NK cell-activating ligands and increasing the sensitivity of HIV-infected cells to lysis by NK cells.
RESULTS

HIV accessory proteins alter NKG2D ligand expression
To better understand the factors that influence the recognition of HIV-infected cells by NK cells, we used a recombinant fusion protein of human NKG2D and the crystallizable fragment of immunoglobulin to directly measure the expression of NKG2D ligands on primary T cells. Infection with HIV encoding all of the viral accessory proteins (Nef, Vif, Vpu and Vpr; Fig. 1a ) resulted in about threefold higher expression of NKG2D ligands than in mock-infected cells ( Fig. 1b) . We consistently obtained that result, with upregulation varying from about 1.5-fold to 5-fold ( Fig. 1c ). However, expression was even higher in cells infected with HIV lacking Vif expression ( Fig. 1b) . Compilation of the data showed consistently and significantly higher ligand expression that was on average 1.5-fold higher than expression after infection with wild-type HIV (Fig. 1c) . As reported before 23 , infection with HIV lacking Nef also yielded higher ligand expression ( Fig. 1b,c) . Infection of T cells with HIV lacking expression of both Vif and Nef resulted in ligand expression similar Producer:
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Lenti Figure 1 Expression of NKG2D ligands in HIV-infected cells. (a) Genome of the HIV vector NL-PI (derived from the NL4-3 HIV molecular clone 12, 40 to that achieved with each single HIV mutant, which suggested that Vif and Nef act on the same pathway.
In contrast, loss of Vpr resulted in lower expression of NKG2D ligands similar to that in uninfected cells (Fig. 1b,c) . This confirmed that Vpr expression was required for HIV-mediated upregulation of NKG2D ligands 20 . Examination of ligand expression by cells infected with vif − vpr − or nef − vpr − double-mutant HIV showed that all of the additional ligand upregulation observed in the absence of Vif and Nef depended on Vpr expression ( Fig. 1d,e ).
To confirm that the ligand phenotype we observed was due to alteration in Vif expression by vif − HIV, we demonstrated that this phenotype was 'rescued' by transduction of a lentiviral vector expressing wild-type Vif in the HIV-infected target cells ( Fig. 1f , left). The expression of Vif achieved by transduction of the lentivirus was less than that of wild-type Vif (Fig. 1g , left); this difference may explain the partial 'rescue' . In contrast, expression of Vif in the virusproducing cells similar to that achieved by wild-type HIV (Fig. 1g , right) did not significantly alter ligand expression by the infected cells ( Fig. 1f, right) . These data confirmed that Vif expression in HIVinfected target cells resulted in less Vpr-dependent upregulation of NKG2D ligands.
A3G expression correlates with upregulation of NKG2D ligand
Because Vif targets A3G for degradation, we sought to determine whether the effects of Vif on the expression of NKG2D ligands were related to A3G. Among samples from uninfected donors, the amount of baseline A3G protein was highly variable ( Fig. 2a) . In addition, we found higher A3G expression after incubation of CD56 − CD8 − target cells with conditioned supernatants from peripheral blood mononuclear cell cultures depleted of CD8 + cells ( Fig. 2a,b) . We also noted that the surface expression of NKG2D ligands was higher after this treatment ( Fig. 2c, left) . The variation in the amount of A3G protein across donors correlated with the expression of NKG2D ligands (Fig. 2d) .
In samples from some donors, we also observed more A3G in primary T cells treated with HIV lacking Vif expression or containing mutant Vif defective in binding and degrading A3G 24 ( Fig. 2e-g) . Results are presented relative to those of control cells treated with medium. Each symbol represents a different donor (independent donors in g and h (n = 5)); small horizontal lines indicate the mean. *P < 0.05 (paired t-test). (i) A3G expression (as in g) versus the expression of NKG2D ligand by mock-infected cells or cells infected with NL-PIvif − (as in d); each symbol represents a different donor. R 2 = 0.66 (mock-infected) or 0.84 (NL-PIvif − ); P < 0.0001 (one-tailed t-test).
(j) Expression of NKG2D ligand by cells infected with wild-type or mutant NL-PI, presented as in g. *P < 0.02 (paired t-test). Data are representative of three experiments with three independent donors (a,c-g), five experiments with five independent donors (h), three experiments with three independent donors (i) or eight experiments with eight independent donors (j).
A r t i c l e s
The greater abundance of A3G after treatment with HIV containing that mutant Vif was less than its abundance after treatment with vif − HIV in some donors, which may indicate this mutation was incompletely defective. Mutation of vpr had no further effect on A3G relative to its abundance after treatment with vif − HIV ( Fig. 2g) . Furthermore, intracellular staining and flow cytometry showed that A3G expression was higher in cells infected with vif − HIV (positive for group-associated antigen (Gag)) than in uninfected cells in the culture or in mock-infected cells (Fig. 2h) . These data support the conclusion that in the absence of Vif, HIV infection can induce A3G expression in infected cells from most donors. Overall, we noted a positive correlation across multiple donors between A3G expression, as determined by immunoblot analysis, and the induction of NKG2D ligand expression for both infected and uninfected cells, with a significant additional effect of infection ( Fig. 2i) . These data supported the possibility that A3G expression determines the extent to which NKG2D ligands are upregulated. We then examined NKG2D expression on cells infected with HIV expressing the mutant Vif unable to bind or degrade A3G. We found that cells infected with this mutant HIV had expression of NKG2D ligand similar to that of cells infected with Vif-deficient HIV (Fig. 2j) . This indicated that the ability of Vif to limit the expression of NKG2D ligands was secondary to its ability to bind A3G.
A3G activates the DNA-damage-response pathway
Published reports have indicated that activation of the DNA-damageresponse pathway can lead to higher expression of NK cell-activating ligands 25 . DNA damage results in phosphorylation of the cyclindependent kinases ATR and ATM and phosphorylation of the checkpoint kinases Chk1 or Chk2, which inhibit cell-cycle progression and promote DNA repair. Distinct types of damage activate these pathways. For example, ATR is activated in response to exposed stretches of single-stranded DNA, whereas ATM is activated in response to double-stranded DNA breaks 26 .
To determine whether the DNA-damage-response pathway is linked to A3G expression and/or upregulation of NKG2D ligands in HIV-infected cells, we measured the effect of HIV infection on the phosphorylation of Chk1 and Chk2. We observed that HIV infection resulted in several-fold more Chk2 phosphorylation ( Fig. 3a,b ). Moreover, we noted even more phosphorylated Chk2 in cells infected with vif − HIV ( Fig. 3a,b ). HIV infection also influenced Chk1 phosphorylation in cells from some donors, although to a lesser degree than its influence on Chk2 phosphorylation (Fig. 3a,c) . Notably, Chk2 phosphorylation was affected by HIV in a manner that mirrored the induction of NKG2D ligands in that it was Vpr dependent and attenuated by Vif expression ( Figs. 3b and 2j) .
We also observed that the magnitude of Chk2 phosphorylation correlated with A3G expression in cells infected with vif − HIV and mock-infected control cells (for multiple donors), but the slope of the regression line was significantly higher for HIV-infected cells (Fig. 3d) . In contrast, when we compared A3G expression with Chk1 phosphorylation (for multiple donors), we found no significant correlation, and cells infected with vif − HIV were indistinguishable from mock-infected cells (Fig. 3e) . Although this suggested that Chk2 is more important than Chk1 for this response, higher background expression of Chk1 than Chk2 may have limited our ability to detect changes in the infected subpopulation.
Given the finding that A3G expression correlated best with Chk2 phosphorylation, we predicted that A3G was activating an ATM pathway. Consistent with our prediction, we observed more phosphorylation of ATM in HIV-infected cells, and we found that ATM phosphorylation was enhanced in cells infected with vif − HIV (Fig. 3f) . In addition, we found that treatment with the ATM inhibitor KU55933 (ref. 27 ) resulted in significantly less upregulation of NKG2D ligand after infection with wild-type or vif − HIV than did treatment with solvent alone (Fig. 3g) . Furthermore, after treatment with KU55933, cells infected with vif − HIV no longer had significantly higher expression of NKG2D ligands than did cells infected with wild-type HIV (Fig. 3g) , which further indicated that A3G-mediated upregulation of NKG2D ligands was ATM dependent. However, total expression of NKG2D ligands remained threefold higher in HIV-infected cells treated with KU55933 than in mock-infected cells (Fig. 3g) . The partial inhibition by KU55933 was consistent with the fact that Vpr can also upregulate NKG2D ligands via the ATR pathway 20 .
To determine whether the observed greater Chk2 phosphorylation in cells infected with vif − HIV was also ATM dependent, we measured Chk2 phosphorylation in KU55933-treated primary T cells infected with vif − HIV. As predicted, we found that treatment with KU55933 resulted in less phosphorylation of Chk2 in primary T cells infected with vif − HIV (Fig. 3h) . These data supported a model in which A3G upregulates NKG2D ligands through an ATM pathway and in which Vif counteracts this upregulation by decreasing A3G expression.
A3G sensitizes HIV-infected T cells to lysis by NK cells
To assess the relevance of the expression of NK cell ligands to the recognition of HIV-infected cells by NK cells and to determine whether Vif might protect infected cells from lysis by NK cells by degrading A3G, we used a published flow cytometry killing assay 12 . For this assay system, we incubated target cells prelabeled with the cytosolic dye CFSE with medium or with unlabeled, highly purified, autologous NK cells. Immediately afterward, we stained the cell mixtures with antibodies to the NK cell markers CD16 and CD56 as well as the vital dye 7-amino-actinomycin D (7-AAD) to discriminate live and dead cells. We then counted 7-AAD − CD16 − CD56 − CFSE + cells as a function of a defined number of inert counting beads added just before flow cytometry. When we tested this assay system with the highly sensitive K562 human myelogenous leukemia cells, which lack MHC class I and have high expression of NK cell-activating ligands, the addition of primary NK cells resulted in considerably fewer living CFSE + target cells (Supplementary Fig. 1) .
To assess the lysis of HIV-infected primary T lymphocytes by NK cells, we infected cells with HIV expressing a green fluorescent protein (GFP) reporter inserted into the open reading frame of the gene encoding the envelope protein to distinguish infected cells from uninfected cells (Fig. 4a) . On day 2 of infection, we incubated autologous NK cells for 4 h together with the infected cells and then analyzed the mixtures to detect lysis by NK cells (as described for Supplementary Fig. 1) . We found that a large fraction of HIV-infected primary T lymphocytes survived treatment with autologous NK cells, whereas K562 cells were completely killed (Fig. 4b,c) . At the highest ratio of effector cells to target cells tested, 47% of the HIV-infected primary T lymphocytes survived, compared with <1% survival of K562 cells (Fig. 4c) .
To determine whether inefficient killing resulted from deficient activation of NK cells, we constructed an HIV genome that overexpressed the NKG2D-activating ligand ULBP1 with or without a fulllength nef open reading frame (Fig. 4a) . Primary T cells infected with ULBP1-overexpressing HIV expressed roughly 40-fold more ULBP1 on their surface than did cells infected with control HIV not overexpressing ULBP1 (Fig. 4d) . We found that ULBP1 overexpression enhanced the clearance of HIV-infected cells by NK cells approximately tenfold (Fig. 4b,c) , which suggested that expression of the NKG2D-activating ligand was limiting for the lysis of HIV-infected primary T cells by NK cells. 
A r t i c l e s
We next sought to determine whether overexpression of activating ligands would affect the recognition by NK cells of infected cells with normal MHC class I expression. To assess this, we infected primary T cells with nef − HIV with or without ULBP1 overexpression. In the absence of ligand overexpression, these cells were more sensitive to lysis by NK cells than were mock-infected cells (Fig. 4e,f) , which indicated that infection with HIV activated lysis by NK cells even without down-modulation of MHC class I. These data were consistent with our observation that HIV infection upregulated NKG2D-activating ligands. However, overexpression of NK cell-activating ligands in infected cells resulted in even more killing and loss of most of the remaining cells (Fig. 4e,f) . These data indicate that in the presence of large amounts of NKG2D ligands, down-modulation of MHC class I is not essential for efficient lysis by NK cells.
To determine whether the inhibitory effect of Vif on the upregulation of NKG2D ligands was physiologically relevant, we assessed whether Vif expression affected the lysis of infected cells by NK cells. Analysis of infected cells showed that cells infected with vif − HIV were significantly more sensitive to recognition by NK cells than were control cells infected with wild-type HIV in a 4-hour cytotoxicity assay (mean survival, 60% and 66% for wild-type HIV compared with 38% and 45% for vif − HIV, at effector/target ratios of 5:1 and 2:1, respectively; Fig. 5a ). Thus, Vif expression resulted in greater survival of HIV-infected T cells.
We then sought to determine whether A3G expression influenced recognition by NK cells through the knockdown of A3G expression by RNA-mediated interference. To accomplish this, we constructed a lentiviral vector expressing short hairpin RNA (shRNA) directed against A3G and GFP, which allowed us to gate on the cells in which A3G was knocked down and assess survival in the presence of NK cells by a flow cytometry killing assay. As a control, we determined that expression of the shRNA-containing vector resulted in less A3G in transfected 293 human embryonic kidney cells (Fig. 5b) . When we transduced primary T cells with lentivirus expressing negative control shRNA or shRNA targeting A3G and infected them with vif − HIV, we found that knockdown of A3G resulted in significantly improved survival of infected cells incubated together with autologous NK cells (Fig. 5c,d) . These data indicate that A3G sensitizes infected cells to lysis by NK cells and that Vif-dependent degradation of A3G probably explains the protective effect of Vif (Fig. 5a) .
Vif and Vpr diminish uridine incorporation
Because A3G deaminates cytosine to uracil, it is possible that the presence of uracil in DNA is sufficient to cause upregulation of NK-activating ligands. Alternatively, gaps and breaks created by the cellular repair of uridine-containing DNA could be responsible. To distinguish between those two possibilities, we directly measured the effect of Vpr and Vif on the incorporation of uridine. The assay we developed to measure uridine incorporation uses the activity of recombinant uracil DNA glycosylase (UDG), which specifically removes uracils and creates an abasic site that no longer serves as a template for PCR. In this assay, incorporation of uridine is detected by less amplification of the template after treatment with UDG. As a control, we generated PCR products that contained or lacked uridine and demonstrated that amplification of templates containing uridine was specifically inhibited by treatment with UDG ( Fig. 6a) .
For DNA prepared from infected primary T cells, treatment with UDG did not affect the amplification of wild-type HIV proviral DNA (Fig. 6b) , which indicated that there was no detectable uridine in this sample. However, UDG had a significant effect on the amplification of proviral DNA from cells infected with vif − vpr − HIV (Fig. 6b) , which indicated the presence of uridine in the DNA from this sample. There was no significant effect of UDG on the amplification of proviral DNA from cells infected with vif − HIV or vpr − HIV, which suggested that Vif and Vpr can independently limit the incorporation of uridine. We noted a similar pattern of sensitivity to UDG when we amplified sequences from a cellular gene (encoding β-actin; Fig. 6b) , and sensitivity to UDG positively correlated with infection rate for DNA isolated from cells infected with vif − vpr − HIV (Fig. 6c) . Thus, these data indicate that uridine can also be incorporated into cellular genomic DNA isolated from infected cells.
We also recovered significantly less HIV DNA from cells infected with vif − vpr − HIV than from cells infected with wild-type HIV after normalization for infection rate and cellular DNA content (Fig. 6d) . By comparison, the amount of cellular DNA recovered from each sample, as measured by amplification of β-actin, was somewhat greater after infection with vif − vpr − HIV (Fig. 6e) . The relatively low recovery of vif − vpr − HIV DNA was not explained by differences in the ability of the polymerase to amplify uridine-containing DNA; control uridine-containing templates were amplified as efficiently A r t i c l e s as were templates that did not contain uridine (Fig. 6f) . Thus, the vif − vpr − provirus seemed to be less stable after infection of primary T cells. The synergistic effect of mutating both vif and vpr was consistent with our hypothesis that both Vif and Vpr act on the same pathway to stabilize the provirus.
Vpr-UNG2 interaction and upregulation of NKG2D ligands
Given the finding that uridine was detectable only in cells infected with vif − vpr − HIV and that cells infected with vif − vpr − HIV had low ligand expression, we concluded that uridine itself was not sufficient to induce ligand expression. Thus, we hypothesized that it was the repair of uridine-containing DNA that was responsible for the Vprand A3G-dependent upregulation of NK cell-activating ligands. In this model, the effects of Vpr on the expression of NKG2D ligands would be mediated by interaction with the uracil glycosylase UNG2.
To test this, we constructed HIV containing vpr with a mutation in sequence encoding the UNG2-binding domain 28 . The Vpr phenotype was masked in the presence of Vif or Nef (Fig. 1c,e) . Therefore, to focus on a potential UNG2-binding phenotype, we tested this Vpr mutant on a nef − background. As predicted, we found that this mutant was less able to induce expression of NK cell-activating ligands than was wild-type Vpr (Fig. 7a) , which indicated that at least a component of the effect of Vpr on ligand expression required UNG2 binding. Alteration of the UNG2-binding site of Vpr by mutation of vpr did not completely eliminate the upregulation of NKG2D ligands; thus, we cannot rule out the possibility that Vpr also upregulates ligands through interactions with other cellular factors, such as SMUG1.
To confirm that UNG2 had a role in the process described above, we knocked down UNG2 expression and assayed NKG2D ligands in HIV-infected primary T lymphocytes. UNG2 expression was 85% lower in the human T lymphoblastoid cell line CEM-SS transduced with lentivirus expressing UNG2-specific shRNA than in control CEM-SS cells transduced with lentivirus expressing negative control shRNA (Fig. 7b) . Consistent with our model, knockdown of UNG2 in primary T cells also resulted in less upregulation of NKG2D ligands by wild-type HIV than that in wild-type HIV-infected cells expressing control shRNA (Fig. 7c) . Once again, the expression of NKG2D ligands was not completely inhibited by knockdown of UNG2 expression, which potentially indicates the involvement of other cellular factors. In sum, however, these data support a model in which Vpr induces the upregulation of NKG2D ligands in HIV-infected T cells by stimulating UNG2-dependent repair of uridine-containing DNA (Supplementary Fig. 2) .
DISCUSSION
Members of the APOBEC-AID family of cytidine deaminases are key host factors that help in the defense against pathogens. There is growing evidence of overlapping roles for these deaminases in alerting killer T cells to infection and DNA damage. For example, A3G has been shown to stimulate recognition by CTLs through the generation of defective translation products 29 . In addition, the DNA 'damage' that results from AID-mediated somatic hypermutation leads to upregulation of NK cell-activating ligands that transiently mark these cells as potentially dangerous 30 . We have now shown that like AID, A3G sensitized cells to recognition by NK cells through upregulation of the expression of NKG2D ligands in HIV-infected cells. Knockdown of A3G enhanced the survival of cells infected with Vif-deficient HIV and incubated with autologous NK cells. In addition, wild-type Vif 
Amplification (copies per µl) 10 A r t i c l e s inhibited the expression of NKG2D ligands, whereas Vif mutants defective in binding and degrading A3G did not. We speculate that these effects on NKG2D ligands may also contribute to the A3Gdependent enhancement of recognition by CTLs 29 , as NKG2D can serve as a costimulatory molecule in CTLs 31 . The effect of AID on the DNA-damage response is related to its cytidine-deaminase activity that results in the incorporation of uridine into cellular genomic DNA. Removal of the uracil by UNG2 and AP endonucleases generates gaps and breaks that lead to activation of the DNA-damage response 32 . In contrast to AID, A3G is a cytoplasmic protein that targets single-stranded DNA, and it is less clear how its expression could lead to the incorporation of uridine into double-stranded cellular DNA and activate the nuclear DNAdamage response. Indeed, a published study did not detect an effect of A3G on the mutation rate of transfected HEK293 human embryonic kidney cells 33 . Thus, the ability of A3G to access cellular DNA seems to be specific to HIV-infected primary T cells that lack Vpr and Vif. The finding that Vif and Vpr specifically inhibited the incorporation of uridine into cellular DNA suggests this is an important cellular response that HIV has evolved to evade.
Although A3G targets single-stranded DNA, and most cellular DNA is double stranded, short stretches of double-stranded DNA have the propensity to temporarily dissociate or 'breathe' 34 , and these may be targeted by A3G in infected cells. In addition, it remains possible that other cytidine deaminases, some of which are nuclear and able to target double-stranded DNA 33 , contribute to the incorporation of uridine into cellular DNA in the setting of HIV infection. Notably, in the absence of Vpr and Vif, we observed not only the incorporation of uridine but also instability of HIV DNA. Thus, the HIV-1 genome is probably the main target of this response, which results in the incorporation of uridine followed by degradation of the HIV-1 DNA in the absence of Vpr and Vif.
We have also shown here that maximal upregulation of NKG2D ligands and the DNA-damage response required Vpr in addition to A3G. One model that explains the combined effects of Vpr and A3G is that Vpr expression is needed to promote the repair of A3G-generated mutations through its interaction with UNG2 (ref. 28 ). This model is consistent with published studies demonstrating that Vpr diminishes the requirement for high Vif expression in the presence of A3G 21 . Moreover, upregulation of NKG2D ligands was less when the UNG2-binding site of Vpr was altered or UNG2 expression was knocked down. Complete reversal of the expression of NKG2D ligands did not occur when UNG2 expression was diminished, either because of incomplete knockdown or because other factors can substitute for UNG2 activity.
The repair of integrated uridine residues decreases the error rate and improves the infectivity of progeny virus. However, the repair process, which generates nicks, gaps and breaks, has the side effect of activating an ATM response that results in the upregulation of NKG2D ligands. The link between this upregulation and deamination indicates broader implications of the intrinsic antiviral response mediated by APOBEC proteins than previously appreciated. Indeed, it seems that the A3G response to infection includes the initiation of a cellular 'suicide mission' meant to contain viral production and spread.
The importance of uridine incorporation as an innate immune response is apparent in the fact that a wide range of viruses have mechanisms to avoid it 35 . In addition, HIV-1 recruits UNG2 to virions, which is reported to enhance viral infectivity by limiting the misincorporation of dUTP during reverse transcription 36 and to excise uridine residues that result from editing by A3G 37 . Thus, there may be multiple routes through which HIV limits uridine incorporation.
Published studies measuring the effect of A3G on the inactivation of viral particles have shown that A3G made in the producer cells and packaged into newly formed virions is required for inactivation of the virus and that A3G in the target cells is dispensable 7 . However, we have provided evidence here that A3G expressed in the target cell also had a role in the innate immune response. Although A3G present in the target cell may be insufficient to inhibit the invading virus from productively infecting the cell, our data indicated that A3G expression in target cells was required for the sensitization of HIV-infected cells to lysis by NK cells.
We also reported that infection of primary T cells with Vif-deficient HIV resulted in higher A3G expression in HIV-infected cells from some donors. This response has not been reported before, to our knowledge, and the mechanism is unknown. Single-stranded RNA from influenza virus also increases A3G expression 38 . Although the mechanism for this is unclear, HIV-1 single-stranded RNA binds Tolllike receptors 7 and 8 (ref. 39) . The ligation of pathogen-recognition receptors induces the production of type I interferon, which stimulates A3G expression 2 . Our results indicate the possibility that detection of HIV by the innate immune system could lead to the production of A3G in infected cells. In sum, the data presented here have demonstrated that A3G expression enhanced the recognition of HIV-infected cells by NK cells through upregulation of NKG2D-activating ligands. Thus, therapeutic strategies aimed at augmenting the antiviral activity of A3G may have the added benefit of promoting immune-system clearance of virus-infected cells by NK cells.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/. 
ONLINE METHODS
Cell culture and viral infection.
Pre-existing bags of fresh human blood cells collected from normal peripheral blood by automated apheresis (Leukopaks) lacking subject identifiers were obtained from The New York Blood Center. The use of these specimens was reviewed by the institutional review board of University of Michigan and was found not to be research of human subjects. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque density separation. CD56 + NK cells were prepared from nonadherent PBMCs with an EasySep kit (StemCell Technologies). After isolation, CD56 + cells were maintained in RPMI-1640 medium with 10% (vol/vol) human AB serum (Fisher Scientific), penicillin, streptomycin, l-glutamine and recombinant human interleukin 2 (500 IU/ml) 41 . PBMCs were prepared for infection with HIV as described 14 , except they were also depleted of CD56 + cells with an EasySep kit (StemCell Technologies). Virus production and infection of PBMCs have been described 12, 42 . Viral constructs. HIV NL-PI and the NL-PInef − , NL-PIvpr − , NL-PIvpu − and NL-PIvpr − nef − accessory protein mutants have been reported 12, 40 . For disruption vif expression, the NdeI site at position 83 was filled in with Klenow polymerase and religated; for disruption of nef expression, the XhoI site at position 101 was similarly filled in and religated. A standard PCR-based mutagenesis strategy (primers, Supplementary Table 1 ) was used for the generation of NL-PIvif(Y44A) (HIV expressing mutant Vif defective in binding and degrading A3G) and NL-PIvpr(W54R) (HIV containing vpr with a mutation in sequence encoding the UNG2-binding domain).
Expression constructs of shRNA targeting A3G and UNG2 (primers, Supplementary Table 1) were cloned into the FG12 lentiviral vector 43 as described 42 . The negative control vector FG12 expressing negative control shRNA has been described 42 .
For construction of the expression vector for Vif, Vif protein of the NL4-3 HIV molecular clone was amplified by PCR (primers, Supplementary Table 1 ) and cloned into the BamHI and NotI sites of the FG9 lentiviral vector 44 .
For construction of the ULBP1-overexpressing HIV plasmid pNL-GIulbp1 + , ulbp was amplified from cDNA ( Supplementary Table 1 ; MegaMan Human Trascriptome Library, Stratagene) and a PCR-based strategy was used to create the IRESulbp1 cassette from the amplicon (primers, Supplementary  Table 1 ). The cassette was cloned into the NheI and BglII sites in the open reading frame of the gene encoding the envelope protein in pNL-G (pNL4-3-∆E-EGFP) 45 .
Flow cytometry. Cell surface proteins (except NKG2D ligands) were stained in flow cytometry buffer (2% (vol/vol) FBS, plus 1% (vol/vol) human type AB serum 1% (vol/vol) HEPES, pH 7.2, and 1% (vol/vol) NaN 3 in PBS) with primary antibodies ( Supplementary Table 2 ) and fluorescence-conjugated isotype-specific secondary antibodies (Invitrogen or Caltag), then were fixed in 2% (wt/vol) paraformaldehyde. For analysis of NKG2D ligands, cells were stained with recombinant fusion protein of human NKG2D and the crystallizable fragment of immunoglobulin (1299NK; R&D Systems); the secondary antibody for this staining was allophycocyanin-conjugated goat antibody to human crystallizable fragment (109-126-098, Jackson ImmunoResearch). Cells were also stained with antibody to CD3 (anti-CD3; 555337; BD Pharmingen; Supplementary Table 2 ) and the secondary antibody AlexaFluor 488conjugated goat antibody to immunoglobulin G2a (A21131; Invitrogen). Cells were stained in flow cytometry buffer without human serum and were gated on CD3 + cells for analysis. Intracellular staining of Gag was done as described 46 with monoclonal antibody KC57 (Beckman Coulter). For A3G staining, cells were fixed, made permeable in 90% (vol/vol) methanol and blocked in 1% (wt/vol) BSA and 10% (vol/vol) goat serum in PBS before being stained with anti-A3G (54257; Abcam) or normal rabbit serum control (Santa Cruz) in 1% (wt/vol) BSA in PBS. Cells were subsequently stained for 30 min at 25 °C with anti-Gag (31-90-25; American Type Culture Collection) conjugated to Alexa Fluor 649 with a kit according to the manufacturer's protocol (PI53050; Pierce). Secondary antibody for A3G staining was Alexa Fluor 488-conjugated goat anti-rabbit (A-1108; Invitrogen) or fluorescein isothiocyanate-conjugated goat anti-rabbit (ALI 3408; Biosource International) diluted in 1% (wt/vol) BSA in PBS.
NK cell cytotoxicity. Target cells (K562 cells and HIV-1-infected and mockinfected primary T lymphocytes) were labeled with 500 µM CFSE (carboxyfluorescein succinimidyl ester; Invitrogen) 1 d before the NK cell assay and were incubated overnight at 37 °C. Alternatively, target cells were infected with shRNA-expressing lentivirus FG12 (that expresses GFP) or GFP-expressing NL-G virus. Labeled target cells were incubated for 4 h at 37 °C together with purified, autologous NK cells at increasing ratios of effector cells to target cells and then were stained for surface MHC class I (HLA-Bw4 (A9 or A32) or HLA-Bw6 (B77; both from One Lambda), depending on the donor) with secondary antibody phycoerythrin-conjugated goat antibody to immunoglobulin M (AM14607; Biosource); with anti-PLAP (8B6, Sigma-Aldrich) and the secondary antibody Alexa Fluor 647-conjugated goat antibody to immunoglobulin G2a); with phycoerythrin-indodicarbocyanine-conjugated anti-CD56 (555517) and anti-CD16 (555408; both from BD Pharmingen); and 7-AAD (Calbiochem). Live target cells were identified by light-scatter parameters, 7-AAD exclusion and staining as CD56 − CD16 − CFSE + (or GFP + ). A constant number of fluorescent CountBright Absolute Counting Beads (Invitrogen) was added to each tube and beads were counted during cytometry acquisition. The normalized number of live cells was calculated as the number of cells multiplied by the fraction of beads counted. The survival of target cells was determined as the percent of normalized target cells that remained after incubation with NK cells.
Immunoblot analysis.
At 48 h after HIV infection, lysates of PBMCs were isolated as described 47 and analyzed by immunoblot (antibodies, Supplementary Table 2 ). Membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (046120; Invitrogen) and developed. After subtraction of background, median band intensities were determined with Adobe Photoshop and normalized to the intensity of tubulin for quantification.
Quantitative PCR analysis. Infected cells were collected 48 h after infection.
For DNA extraction, cells were resuspended in PBS and lysed with MagNA Pure Lysis/Binding Buffer (Roche). Lysed cells were loaded onto a MagNA Pure Compact and total DNA was extracted. Samples were treated with 10 U UDG (NEB) and incubated at 37 °C for 1 h followed by incubation for 10 min at 95 °C for inactivation of UDG. For samples treated with heat-inactivated UDG, DNA was added after heat inactivation of UDG.
For quantitative PCR analysis, a TaqMan ProbeMaster kit (Roche) and the appropriate primers ( Supplementary Table 3 ) were used. HIV-1 DNA was first subjected to 12 cycles of linear amplification with the primer second-LTR-F-univ 46 for amplification of the negative strand. Probe-2 has been described 48 .
Control thymidine-and uridine-containing templates were generated by PCR amplification of NL-PI with the primers second-LTR-F-univ and Gag-R-3. For uridine control templates, dUTP was used instead of dTTP. Gel-purified thymidine-and uridine-containing control templates were analyzed by gel electrophoresis of reamplified samples after treatment with UDG.
Statistical analysis. The statistical significance of the flow cytometry and immunoblot data was assessed by a paired t-test. GraphPad Prism software was used for regression analysis.
For quantitative PCR data, amplification efficiency (E) was calculated as E = 10 (1 / slope of target standard curve) -1. The average quantification cycle (Cq) value for three replicates of each sample was converted to Cq at 100% efficiency (Cq 100 = Cq × log 2 (1 + E)) to permit comparison of different genes. The change in cycling threshold (∆C T ) was calculated for each sample (as the Cq 100 of the untreated sample minus the Cq 100 of the UDG-treated) sample) and was converted to a quantity ratio (2 ∆CT ). One-sample t-tests were used for comparison of C T values and quantity ratios to the expected values if treatment with UDG had no effect (0 and 1, respectively). Total HIV-1 DNA was assessed by calculation of ∆C T values for samples not treated with UDG relative to that of β-actin and ∆∆C T values comparing each mutant virus to NL-PI. The ∆∆C T values were converted to quantity ratios and normalized to infection rate. One-sample t-tests were used for comparison of the normalized quantity ratios to the expected value of 1 if HIV-1 DNA amplification did not vary with mutation of vif or vpr.
